| P50 | author | Costas Giaginis | Q79628281 |
| | Stamatios Theocharis | Q88269713 |
| P2093 | author name string | Ioannis Koutsounas | |
| | Efstratios Patsouris | |
| P2860 | cites work | [Expression of KiSS-1mRNA in pancreatic ductal adenocarcinoma and non-cancerous pancreatic tissues in SD rats]. | Q53335982 |
| | Effect of sodium butyrate, a differentiating agent, on cell surface glycoconjugates of a human pancreatic cell line. | Q53517672 |
| | Decreased expression of transforming growth factor alpha during differentiation of human pancreatic cancer cells | Q67593971 |
| | Differential effects of sodium butyrate and hexamethylene bisacetamide on growth and secretion of cultured human endocrine tumor cells | Q67685644 |
| | Ultrastructural differentiation and CEA expression of butyrate-treated human pancreatic carcinoma cells | Q69002043 |
| | Modulation of enzymatic activities during spontaneous and induced differentiation in a human pancreatic adenocarcinoma cell line CAPAN-1 | Q69350563 |
| | Differentiation of pancreatic carcinoma induced by retinoic acid or sodium butyrate: a morphological and molecular analysis of four cell lines | Q71672648 |
| | Modification of antigen expression in human and hamster pancreatic cancer cell lines induced by sodium butyrate | Q72667122 |
| | Effects of sodium butyrate and dimethylsulfoxide on human pancreatic tumor cell lines | Q72727739 |
| | Histone acetylation and cancer | Q75200335 |
| | Apoptosis, proliferation and differentiation patterns are influenced by Zebularine and SAHA in pancreatic cancer models | Q79453002 |
| | Histone deacetylase inhibitors: Potential in cancer therapy | Q24649025 |
| | Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling | Q28238147 |
| | Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells | Q28245307 |
| | Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors) | Q28302246 |
| | Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells | Q28366303 |
| | FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 |
| | The mammalian epigenome | Q29615763 |
| | Pancreatic cancer | Q29616288 |
| | Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 |
| | High class I HDAC activity and expression are associated with RelA/p65 activation in pancreatic cancer in vitro and in vivo | Q30884835 |
| | Identification of the regulatory proteins in human pancreatic cancers treated with Trichostatin A by 2D-PAGE maps and multivariate statistical analysis. | Q31095355 |
| | Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells | Q31792962 |
| | Proteomic profiling of pancreatic ductal carcinoma cell lines treated with trichostatin-A. | Q33187257 |
| | Epigenetic down-regulation of CDKN1C/p57KIP2 in pancreatic ductal neoplasms identified by gene expression profiling | Q33218332 |
| | A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer | Q33367733 |
| | Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer | Q33372697 |
| | Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group | Q33385281 |
| | Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. | Q33390876 |
| | Melding a New 3-Dimensional Agarose Colony Assay with the E(max) Model to Determine the Effects of Drug Combinations on Cancer Cells | Q33827019 |
| | Inhibition of histone deacetylase activity by butyrate | Q34211186 |
| | Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers | Q34493610 |
| | Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate | Q34550827 |
| | Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer | Q34570210 |
| | Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer | Q34613161 |
| | Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group | Q34622291 |
| | Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay | Q34656429 |
| | Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors | Q34742711 |
| | New directions in the management of advanced pancreatic cancer: a review | Q34770551 |
| | Histone deacetylase inhibitors and anticancer therapy | Q35100487 |
| | A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors | Q35134137 |
| | Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro | Q40444098 |
| | FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells | Q40591467 |
| | Butyrate inhibits pancreatic cancer invasion | Q40621145 |
| | Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma. | Q40654622 |
| | Trypsinogen expression by two human pancreatic cell lines CFPAC-1 and CAPAN-1. Modulation during spontaneous and induced cell growth | Q41452783 |
| | Ultrastructural differentiation of sodium butyrate-treated human pancreatic adenocarcinoma cell lines | Q41665981 |
| | Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. | Q42163115 |
| | Preclinical antitumor activity of CI-994. | Q42549496 |
| | Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. | Q42798739 |
| | Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells | Q43809752 |
| | Requirement of a specific Sp1 site for histone deacetylase-mediated repression of transforming growth factor beta Type II receptor expression in human pancreatic cancer cells. | Q44443243 |
| | Acetylated sp3 is a transcriptional activator | Q44499415 |
| | Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. | Q44521103 |
| | Clinicopathological significance and molecular regulation of maspin expression in ductal adenocarcinoma of the pancreas | Q44582125 |
| | Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. | Q44591937 |
| | Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. | Q45055920 |
| | Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid | Q46432924 |
| | Results and follow-up of locally advanced cancer of the exocrine pancreas treated with radiochemotherapy | Q46609999 |
| | MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo | Q46643625 |
| | Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. | Q47860803 |
| | Epigenetic regulation (DNA methylation, histone modifications) of the 11p15 mucin genes (MUC2, MUC5AC, MUC5B, MUC6) in epithelial cancer cells. | Q48079792 |
| | Activation of a human peroxisome proliferator-activated receptor by the antitumor agent phenylacetate and its analogs | Q48940256 |
| | Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. | Q52569752 |
| | Hyaluronic acid butyric esters in cancer therapy | Q36061348 |
| | Histone deacetylase inhibitors: a novel target of anticancer therapy (review). | Q36360003 |
| | Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. | Q36710904 |
| | MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent | Q36769244 |
| | Histone deacetylase inhibitors: molecular mechanisms of action | Q36908440 |
| | Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation | Q36922674 |
| | Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation | Q37172903 |
| | Zn(II)-dependent histone deacetylase inhibitors: suberoylanilide hydroxamic acid and trichostatin A. | Q37251484 |
| | Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead | Q37267985 |
| | BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing | Q37268123 |
| | Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors | Q37284812 |
| | Epidemiology of pancreatic cancer: an overview | Q37608905 |
| | Epigenetics and cancer treatment | Q37616426 |
| | Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor | Q37873498 |
| | Regulation of the human O(6)-methylguanine-DNA methyltransferase gene by transcriptional coactivators cAMP response element-binding protein-binding protein and p300. | Q38309365 |
| | Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex | Q38332130 |
| | Epigenetic regulation and molecular characterization of C/EBPalpha in pancreatic cancer cells | Q38358635 |
| | Epigenetic silencing of MicroRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer | Q39514896 |
| | HDAC2 mediates therapeutic resistance of pancreatic cancer cells via the BH3-only protein NOXA. | Q39837701 |
| | Combined targeting of histone deacetylases and hedgehog signaling enhances cytoxicity in pancreatic cancer. | Q39855695 |
| | Synergistic effect of trichostatin A and 5-aza-2'-deoxycytidine on growth inhibition of pancreatic endocrine tumour cell lines: a proteomic study. | Q39871548 |
| | Effect of trichostatin a on viability and microRNA expression in human pancreatic cancer cell line BxPC-3. | Q39900934 |
| | Epigenetic regulation of the human mucin gene MUC4 in epithelial cancer cell lines involves both DNA methylation and histone modifications mediated by DNA methyltransferases and histone deacetylases | Q39980309 |
| | Inhibition of human pancreatic cell line MIA PaCa2 proliferation by HA-But, a hyaluronic butyric ester: a preliminary report | Q39988294 |
| | HDAC inhibitors effectively induce cell type-specific differentiation in human glioblastoma cell lines of different origin. | Q39999407 |
| | Histone deacetylase (HDAC) encoding gene expression in pancreatic cancer cell lines and cell sensitivity to HDAC inhibitors. | Q40009367 |
| | The combination of the histone-deacetylase inhibitor trichostatin A and gemcitabine induces inhibition of proliferation and increased apoptosis in pancreatic carcinoma cells. | Q40098977 |
| | Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors | Q40115917 |
| | Synergistic inhibition of pancreatic adenocarcinoma cell growth by trichostatin A and gemcitabine. | Q40122559 |
| | Proteomic analysis of pancreatic endocrine tumor cell lines treated with the histone deacetylase inhibitor trichostatin A. | Q40143851 |
| | Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells | Q40148122 |
| | Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues | Q40172155 |
| | Inhibition of histone deacetylation does not block resilencing of p16 after 5-aza-2'-deoxycytidine treatment | Q40185335 |
| | The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer | Q40187997 |
| | Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells | Q40197237 |
| | Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells | Q40198503 |
| | Histone deacetylase inhibitor trichostatin A and proteasome inhibitor PS-341 synergistically induce apoptosis in pancreatic cancer cells | Q40244404 |
| | Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity | Q40253974 |
| | MUC2 expression is regulated by histone H3 modification and DNA methylation in pancreatic cancer | Q40276044 |
| | Trichostatin A enhances the response of chemotherapeutic agents in inhibiting pancreatic cancer cell proliferation. | Q40299140 |
| | Aberrant expression of N-acetylglucosaminyltransferase-IVa and IVb (GnT-IVa and b) in pancreatic cancer | Q40325695 |
| | Significance of cellular distribution of ezrin in pancreatic cystic neoplasms and ductal adenocarcinoma | Q40338393 |
| | Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways | Q40383741 |
| | Histone deacetylase inhibitors induced caspase-independent apoptosis in human pancreatic adenocarcinoma cell lines. | Q40386572 |
| | SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines | Q40399017 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 813-828 | |
| P577 | publication date | 2013-02-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Current evidence for histone deacetylase inhibitors in pancreatic cancer | |
| P478 | volume | 19 | |